Biogen Idec Inc (BIIB) 341.24 $BIIB
US CNS Disorders Drug Pipeline Insight 2014
M2 - 1 hr 17 mins ago
Research and Markets (http://www.researchandmarkets.com/research/j85brc/us_cns_disorders) has announced the addition of the "US CNS Disorders Drug Pipeline Insight 2014" report to their offering. The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. The numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market. Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer's markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each. Key Topics Covered: 1. Introduction to Central Nervous System (CNS) Disorder 2. US Central Nervous System (CNS) Disorder Market Overview 3. US Central Nervous System (CNS) Disorder Incidence by Disease 4. US Central Nervous System (CNS) Disorder Market Dynamics 5. US Multiple CNS Disorder Drug Pipeline by Phase & Company 6. US Alzheimer's Disease Drug Pipeline by Phase & Company 7. US Multiple Sclerosis Drug Pipeline by Phase & Company 8. US Parkinson's Disease Drug Pipeline by Phase & Company 9. US CNS Disorder/Neurodegenerative Disorders Drug Pipeline by Phase & Company 10. US Epilepsy Drug Pipeline by Phase & Company 11. US Migraine Drug Pipeline by Phase & Company 12. US Huntington's Disease Drug Pipeline by Phase & Company 13. US Neuropathic Pain Clinical Pipeline by Phase & Company 14. US Schizophrenia Clinical Trial Insight by Phase & Company 15. US Sleep Disorders Drug Pipeline by Phase & Company 16. Competitive Landscape Companies Mentioned: - Alkermes - Allergan - AstraZeneca - Biogen Idec - Bristol-Myers Squibb - Eli Lilly - GlaxoSmithKline - Merck - Novartis - Pfizer - Roche - Sanofi - Sunovion Pharmaceuticals - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/j8..._disorders
Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?
After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?
Biogen names Dr Donald R. Johns VP of its amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub)
M2 - Wed Aug 27, 5:48AM CDT
Medicine company Biogen (NasdaqGS:BIIB) disclosed on Tuesday that it has appointed Dr Donald R. Johns, MD as vice president of its amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub), a new, cohesive unit dedicated to accelerating the discovery and development of novel therapies for ALS.
Celgene, Gilead Lead Big Biotech Stock Movers
at Investor's Business Daily - Tue Aug 26, 4:55PM CDT
Big-cap biotechs moved in strong volume on the stock market today as Deutsche Bank added several to its short-term buy list, after Citi reported back from visits with medical experts. Celgene (CELG) hit a new high above 95 after Deutsche Bank analyst...
Biogen Idec in Panel at the Citi 9th Annual Biotech Conference
Business Wire - Tue Aug 26, 3:01PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will participate in a panel at the Citi 9th Annual Biotech Conference. The webcast will be live on Thursday, September 4, 2014 at 10:00a.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
Economic Data Fuel Another All-Time High For S&P 500
at Investor's Business Daily - Tue Aug 26, 2:36PM CDT
A big jump in durable goods orders and a strong reading on consumer confidence from the Conference Board fueled modest gains for the stock market Tuesday. The Dow Jones industrial average led the way, rising 0.3%. Exxon Mobil (XOM), UnitedHealth...
Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub
Business Wire - Tue Aug 26, 7:00AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that Donald R. Johns, M.D., has joined the company as vice president, leading Biogen Idec's amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub). The ALS iHub is a new, cohesive unit dedicated to accelerating the discovery and development of novel therapies for ALS by integrating research with clinical development. Dr. Johns reports directly to Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer.
Health Canada Approves Eloctate(TM), the First Therapy to Extend the Interval Between Prophylactic Infusions in Hemophilia A
CNW Group - Tue Aug 26, 7:00AM CDT
- Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Regimens of Either Every Three to Five Days or Once-Weekly Infusions -
Biogen, Celgene In Buy Range; LinkedIn Coming Back
at Investor's Business Daily - Mon Aug 25, 5:43PM CDT
Biotech stocks are well represented in this week's Big Cap 20, while LinkedIn (LNKD) and Facebook (FB) are pacing a rebound in Internet stocks. The Medical-Biomedical/Biotech industry has erased slightly more than half its losses since falling...
Stocks Hold Decent Gains; InterMune Deal Sparks Biotechs
at Investor's Business Daily - Mon Aug 25, 1:54PM CDT
Major averages held on to decent gains with a little over one hour remaining in Monday's session. After topping the 2000 level, the S&P 500 rallied 0.5%; the Dow Jones industrial average also gained 0.5% while the Nasdaq tacked on 0.3%. Nasdaq volume...
Majority Of IBD 50 Firms Strong On Sponsorship
at Investor's Business Daily - Fri Aug 22, 5:37PM CDT
Earnings growth fuels a stock's price performance, but that's not the only ingredient for a stock's success. Rising mutual fund sponsorship also helps. Stocks with solid sponsorship aren't hard to find every week in the IBD 50, but sponsorship runs...
Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:35PM CDT
Encouraging data was published on Celgen's (CELG) Revlimid in DLBCL.
Biogen Idec appoints Adriana (Andi) Karaboutis as EVP of its Technology and Business Solutions
M2 - Fri Aug 22, 5:25AM CDT
Medicine company Biogen Idec (NasdaqGS:BIIB) disclosed on Thursday the election of Adriana (Andi) Karaboutis as executive vice president of its Technology and Business Solutions.
Watch for Biogen Idec to Potentially Rebound After Falling 1.15% Yesterday
Comtex SmarTrend(R) - Thu Aug 21, 3:53PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $337.19 to a high of $344.42. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $340.67 on volume of 663,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions
Business Wire - Thu Aug 21, 6:00AM CDT
Biogen Idec (NASDAQ: BIIB) today announced the appointment of Adriana (Andi) Karaboutis as executive vice president, Technology and Business Solutions, effective September 24, 2014. She will report directly to the company's chief executive officer, George Scangos, Ph.D., and will be a member of the Biogen Idec management team.
What Investors Gain from Large, Mid & Small-Cap Growth Funds - Mutual Fund Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 2:02PM CDT
For investors looking to invest in growth funds, we will suggest here the top growth funds from each market capitalization. These funds carry a Zacks Mutual Fund Rank #1 (Strong Buy) as we expect the funds to outperform its peers in the future
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.
US Orphan Drug Clinical Pipeline Insight 2014 - New Report on the $49 Billion Industry
M2 - Wed Aug 20, 8:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q26z36/us_orphan_drug) has announced the addition of the "US Orphan Drug Clinical Pipeline Insight 2014" report to their offering. In 2013, the US market for orphan drugs was estimated worth US$ 49 Billion. With factors like government support, high profitability and many more, this market is expected to surpass US$ 60 Billion by 2018. The orphan drugs enjoy significant competitive advantages owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs. In US, the research & development of orphan drugs is facilitated by public programs, government regulations, and policies. The major incentives for research & development of orphan drug include grants, research support, fee waivers, tax incentives, and orphan drug market exclusivity. In a highly specialized market like that of orphan drugs, though the impact of market exclusivity in the US has been positive yet relatively modest, a special platform for continued orphan drug development has been laid down by the economic incentives and public support mechanisms. US Orphan Drug Pipeline Insight 2014 - Report Highlight: - US Orphan Drug Market Insight & Orphan Drug Designation Criteria - Reimbursement Policy & FDA Regulatory Framework - US Orphan Drug Pipeline by Phase, Indication & Company - Marketed Orphan Drug Clinical Insight - US Orphan Drug Clinical Pipeline: 570 Drugs - Marketed Orphan Drugs in US: 203 Drugs - Majority Orphan Drugs in PHASE-II Development: 207 Drugs Key Topics Covered: 1. Introduction to US Orphan Market - Market Overview - Clinical Pipeline Overview 2. US Orphan Drug Regulatory Framework - Criteria for Orphan Drug Designation - Reimbursement Policy for Orphan Drugs - FDA Regulation 3. US Orphan Drug Clinical Pipeline by Phase, Indication & Company - Unknown - Research - Preclinical - Clinical - Phase-I - Phase-I/II - Phase-II - Phase-II/III - Phase-III - Preregistration - Registered 4. Marketed Orphan Drugs Clinical Insight by Indication & Company 5. Suspended & Discontinued Orphan Drugs in Clinical Pipeline by Phase, Indication & Company - No development reported - Discontinued - Market Withdrawal - Suspended 6. Competitive Landscape - Alexion - Biogen Idec - Bristol Myers Squibb - Celgene - Eli Lilly - Glaxosmithkline - Merck - Novartis Pharmaceuticals - Pfizer - Roche - Rare Disease Therapeutics - Sanofi For more information visit http://www.researchandmarkets.com/research/q2...rphan_drug
US CNS Disorders Drug Pipeline Insight 2014
M2 - 1 hr 17 mins ago
Research and Markets (http://www.researchandmarkets.com/research/j85brc/us_cns_disorders) has announced the addition of the "US CNS Disorders Drug Pipeline Insight 2014" report to their offering. The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. The numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market. Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer's markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each. Key Topics Covered: 1. Introduction to Central Nervous System (CNS) Disorder 2. US Central Nervous System (CNS) Disorder Market Overview 3. US Central Nervous System (CNS) Disorder Incidence by Disease 4. US Central Nervous System (CNS) Disorder Market Dynamics 5. US Multiple CNS Disorder Drug Pipeline by Phase & Company 6. US Alzheimer's Disease Drug Pipeline by Phase & Company 7. US Multiple Sclerosis Drug Pipeline by Phase & Company 8. US Parkinson's Disease Drug Pipeline by Phase & Company 9. US CNS Disorder/Neurodegenerative Disorders Drug Pipeline by Phase & Company 10. US Epilepsy Drug Pipeline by Phase & Company 11. US Migraine Drug Pipeline by Phase & Company 12. US Huntington's Disease Drug Pipeline by Phase & Company 13. US Neuropathic Pain Clinical Pipeline by Phase & Company 14. US Schizophrenia Clinical Trial Insight by Phase & Company 15. US Sleep Disorders Drug Pipeline by Phase & Company 16. Competitive Landscape Companies Mentioned: - Alkermes - Allergan - AstraZeneca - Biogen Idec - Bristol-Myers Squibb - Eli Lilly - GlaxoSmithKline - Merck - Novartis - Pfizer - Roche - Sanofi - Sunovion Pharmaceuticals - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/j8..._disorders
Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?
After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?
Biogen names Dr Donald R. Johns VP of its amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub)
M2 - Wed Aug 27, 5:48AM CDT
Medicine company Biogen (NasdaqGS:BIIB) disclosed on Tuesday that it has appointed Dr Donald R. Johns, MD as vice president of its amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub), a new, cohesive unit dedicated to accelerating the discovery and development of novel therapies for ALS.
Celgene, Gilead Lead Big Biotech Stock Movers
at Investor's Business Daily - Tue Aug 26, 4:55PM CDT
Big-cap biotechs moved in strong volume on the stock market today as Deutsche Bank added several to its short-term buy list, after Citi reported back from visits with medical experts. Celgene (CELG) hit a new high above 95 after Deutsche Bank analyst...
Biogen Idec in Panel at the Citi 9th Annual Biotech Conference
Business Wire - Tue Aug 26, 3:01PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will participate in a panel at the Citi 9th Annual Biotech Conference. The webcast will be live on Thursday, September 4, 2014 at 10:00a.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
Economic Data Fuel Another All-Time High For S&P 500
at Investor's Business Daily - Tue Aug 26, 2:36PM CDT
A big jump in durable goods orders and a strong reading on consumer confidence from the Conference Board fueled modest gains for the stock market Tuesday. The Dow Jones industrial average led the way, rising 0.3%. Exxon Mobil (XOM), UnitedHealth...
Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub
Business Wire - Tue Aug 26, 7:00AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that Donald R. Johns, M.D., has joined the company as vice president, leading Biogen Idec's amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub). The ALS iHub is a new, cohesive unit dedicated to accelerating the discovery and development of novel therapies for ALS by integrating research with clinical development. Dr. Johns reports directly to Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer.
Health Canada Approves Eloctate(TM), the First Therapy to Extend the Interval Between Prophylactic Infusions in Hemophilia A
CNW Group - Tue Aug 26, 7:00AM CDT
- Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Regimens of Either Every Three to Five Days or Once-Weekly Infusions -
Biogen, Celgene In Buy Range; LinkedIn Coming Back
at Investor's Business Daily - Mon Aug 25, 5:43PM CDT
Biotech stocks are well represented in this week's Big Cap 20, while LinkedIn (LNKD) and Facebook (FB) are pacing a rebound in Internet stocks. The Medical-Biomedical/Biotech industry has erased slightly more than half its losses since falling...
Stocks Hold Decent Gains; InterMune Deal Sparks Biotechs
at Investor's Business Daily - Mon Aug 25, 1:54PM CDT
Major averages held on to decent gains with a little over one hour remaining in Monday's session. After topping the 2000 level, the S&P 500 rallied 0.5%; the Dow Jones industrial average also gained 0.5% while the Nasdaq tacked on 0.3%. Nasdaq volume...
Majority Of IBD 50 Firms Strong On Sponsorship
at Investor's Business Daily - Fri Aug 22, 5:37PM CDT
Earnings growth fuels a stock's price performance, but that's not the only ingredient for a stock's success. Rising mutual fund sponsorship also helps. Stocks with solid sponsorship aren't hard to find every week in the IBD 50, but sponsorship runs...
Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:35PM CDT
Encouraging data was published on Celgen's (CELG) Revlimid in DLBCL.
Biogen Idec appoints Adriana (Andi) Karaboutis as EVP of its Technology and Business Solutions
M2 - Fri Aug 22, 5:25AM CDT
Medicine company Biogen Idec (NasdaqGS:BIIB) disclosed on Thursday the election of Adriana (Andi) Karaboutis as executive vice president of its Technology and Business Solutions.
Watch for Biogen Idec to Potentially Rebound After Falling 1.15% Yesterday
Comtex SmarTrend(R) - Thu Aug 21, 3:53PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $337.19 to a high of $344.42. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $340.67 on volume of 663,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions
Business Wire - Thu Aug 21, 6:00AM CDT
Biogen Idec (NASDAQ: BIIB) today announced the appointment of Adriana (Andi) Karaboutis as executive vice president, Technology and Business Solutions, effective September 24, 2014. She will report directly to the company's chief executive officer, George Scangos, Ph.D., and will be a member of the Biogen Idec management team.
What Investors Gain from Large, Mid & Small-Cap Growth Funds - Mutual Fund Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 2:02PM CDT
For investors looking to invest in growth funds, we will suggest here the top growth funds from each market capitalization. These funds carry a Zacks Mutual Fund Rank #1 (Strong Buy) as we expect the funds to outperform its peers in the future
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.
US Orphan Drug Clinical Pipeline Insight 2014 - New Report on the $49 Billion Industry
M2 - Wed Aug 20, 8:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q26z36/us_orphan_drug) has announced the addition of the "US Orphan Drug Clinical Pipeline Insight 2014" report to their offering. In 2013, the US market for orphan drugs was estimated worth US$ 49 Billion. With factors like government support, high profitability and many more, this market is expected to surpass US$ 60 Billion by 2018. The orphan drugs enjoy significant competitive advantages owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs. In US, the research & development of orphan drugs is facilitated by public programs, government regulations, and policies. The major incentives for research & development of orphan drug include grants, research support, fee waivers, tax incentives, and orphan drug market exclusivity. In a highly specialized market like that of orphan drugs, though the impact of market exclusivity in the US has been positive yet relatively modest, a special platform for continued orphan drug development has been laid down by the economic incentives and public support mechanisms. US Orphan Drug Pipeline Insight 2014 - Report Highlight: - US Orphan Drug Market Insight & Orphan Drug Designation Criteria - Reimbursement Policy & FDA Regulatory Framework - US Orphan Drug Pipeline by Phase, Indication & Company - Marketed Orphan Drug Clinical Insight - US Orphan Drug Clinical Pipeline: 570 Drugs - Marketed Orphan Drugs in US: 203 Drugs - Majority Orphan Drugs in PHASE-II Development: 207 Drugs Key Topics Covered: 1. Introduction to US Orphan Market - Market Overview - Clinical Pipeline Overview 2. US Orphan Drug Regulatory Framework - Criteria for Orphan Drug Designation - Reimbursement Policy for Orphan Drugs - FDA Regulation 3. US Orphan Drug Clinical Pipeline by Phase, Indication & Company - Unknown - Research - Preclinical - Clinical - Phase-I - Phase-I/II - Phase-II - Phase-II/III - Phase-III - Preregistration - Registered 4. Marketed Orphan Drugs Clinical Insight by Indication & Company 5. Suspended & Discontinued Orphan Drugs in Clinical Pipeline by Phase, Indication & Company - No development reported - Discontinued - Market Withdrawal - Suspended 6. Competitive Landscape - Alexion - Biogen Idec - Bristol Myers Squibb - Celgene - Eli Lilly - Glaxosmithkline - Merck - Novartis Pharmaceuticals - Pfizer - Roche - Rare Disease Therapeutics - Sanofi For more information visit http://www.researchandmarkets.com/research/q2...rphan_drug
